HALO

Stats

Summary

we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies

Market Cap: 5.3 Billion

Primary Exchange: NASDAQ

Website: https://www.halozyme.com/

Shares Outstanding: 127 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.9423517376000394

Sector: Manufacturing

Industry: Biological Product (except Diagnostic) Manufacturing

Ethical Flags

Longest drawdown: 1283 trading days

From: 2015-07-22 To: 2020-05-08

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor